Ocata Therapeutics Company
%20.jpg)
Ocata Therapeutics, Inc. is a clinical stage biotechnology company focused on the development and commercialization of Regenerative Ophthalmology therapeutics. Ocata’s most advanced products are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration. Ocata’s intellectual property portfolio includes pluripotent stem cell platforms – hESC and induced pluripotent stem cell (iPSC) – and other cell therapy research programs.
Headquarters:
Marlborough, Massachusetts, United States
Employee Number:
11-50
Technology:
Regenerative Medicine
Industry:
Biotechnology, Health Care, Therapeutics
Total Funding:
$82.5M
Estimated Revenue:
$10M to $50M
Investors Number:
13
Investor Type:
For Profit
Founded Date:
1-1
Last Funding Type:
Venture - Series Unknown
Funding Status:
M&A